Can intraprostatic injection of onabotulinumtoxina be benefi cial to treat premature ejaculation ? : results of a prospective study

Abstract EN

We prospectively evaluated effi cacy and adverse eff ects of intraprostatic injections of onabotulinumtoxinA to treat premature ejaculation.

Twentyfour men ≥19 years-old with premature ejaculation for ≥ 6 months and intravaginal ejaculation latency time ≤ 2 minutes underwent transurethral intraprostatic injections of onabotulinumtoxinA (100 U).

Primary endpoint was change of intravaginal ejaculation latency time at 3-months.

Secondary endpoints included changes in premature ejaculation profi le and patientreported global impression of change (PGI).

Mean baseline ejaculation latency time has signifi cantly increased at 1-, 3- and 6-months, respectively.

In premature ejaculation profi le “perceived control over ejaculation”, signifi cant improvement was reported at 3-months, while non-signifi cant changes were reported at 1- and 6-months.

Patients reported non-signifi cant changes of “personal distress related to ejaculation” and “interpersonal diffi culty related to ejaculation”.

Only 8.3%, 12.5% and 12.5% of men reported “better” at 1-, 3- and 6-months, respectively, while all other patients reported “no change” or “slightly better” in patient-reported global impression of change.

No serious adverse eff ects were observed.

Improvements of intravaginal ejaculation latency time were not clinically meaningful, as most men reported “no change” or “slightly better” in patient-reported global impression of change.

These marginal improvements did not support using onabotulinumtoxinA intraprostatic injections to remedy premature ejaculation.